|
|
| 175.92 Net Asset Value | -0.14% 1 Day | -3.20% Year-to-Date | Overall Morningstar Rating |
| Health Style or Category | No Load Sales Expenses | 0.81% Expense Ratio | High Morningstar Risk Rating™ |
| 1 month | -17.61% | 3 years | +31.52% | |
| 3 months | -15.19% | 5 years | +28.01% | |
| 1 year | +27.83% | Since inception | +14.18% |
| FBIOX | Category | |
|---|---|---|
| Performance 5-yr return | +28.01% | +23.71% |
| Expense ratio | 0.81% | 1.46% |
| Risk 5 year sharpe ratio | 1.35 | 1.54 |
| Net assets | $9.4B | $2.6B |
| Average market cap | $10.6B | $31.7B |
| Average P/E | 33.8 | 26.8 |
| Portfolio turnover | 42% | 42% |
There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.
| Fund family | Fidelity Investments |
| Fund manager & tenure | Rajiv Kaul / 8 Years |
| Minimal initial investment | $2,500.00 |
| Minimum IRA investment | $200.00 |
| U.S. stock | 97.51% |
| International stock | 1.69% |
| Cash | 0.57% |
| Other | 0.23% |
| Fixed income | 0.00% |
| Healthcare | 100.00% |
| Business service | 0.00% |
| Consumer goods | 0.00% |
| Consumer service | 0.00% |
| Energy | 0.00% |
| GILD Gilead Sciences Inc | 13.32% |
| AMGN Amgen Inc | 9.05% |
| BIIB Biogen Idec Inc | 6.50% |
| ICPT Intercept Pharmaceuticals Inc | 4.89% |
| ALXN Alexion Pharmaceuticals, Inc. | 4.69% |
| CELG Celgene Corporation | 4.18% |
| REGN Regeneron Pharmaceuticals, Inc. | 3.85% |
| VRTX Vertex Pharmaceuticals Inc | 2.98% |
| BMRN Biomarin Pharmaceutical, Inc. | 1.68% |
| PCYC Pharmacyclics, Inc. | 1.66% |
.
